Profitelligence Profitelligence · Filing Ledger Open JNJ research →

Form 8-K · Current Report · Filed 2025-09-08

Johnson & Johnson Appoints John Morikis to Board of Directors

Johnson & Johnson announced on September 8, 2025, the appointment of John Morikis, retired Chairman, President, and CEO of The Sherwin-Williams Company, to its Board of Directors.

Filer
Johnson & Johnson JNJ · NYSE
Filed
Accession
0000200406-25-000190
CIK
0000200406
Signal
Medium impactHealthcare

Details

Mr. Morikis, a seasoned leader with over four decades of experience in the paint industry, will serve on the Audit Committee and Compensation & Benefits Committee.

Items reported

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

Board Member Appointed

Market reaction

Close before filing

$178.43

Next session

-0.8%

Since filing

+43.7%

Latest close

$256.35

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from JNJ reporting the same item, with the next session's move:

About Johnson & Johnson

Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.

Exchange NYSE Industry Drug Manufacturers - General Company website ↗

Never miss another JNJ filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts